Results 111 to 120 of about 25,087 (209)

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Journal of Translational Medicine
Background Acute myeloid leukaemia (AML) comprises a group of heterogeneous and aggressive haematological malignancies with unsatisfactory prognoses and limited treatment options.
Ying Lu, Xia Jiang, Youhong Li, Fenglin Li, Mengting Zhao, Ye Lin, Lili Jin, Haihui Zhuang, Shuangyue Li, Peipei Ye, Renzhi Pei, Jie Jin, Lei Jiang   +12 more
doaj   +1 more source

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report

Reports
Background and Clinical Significance: Tumor lysis syndrome (TLS) is a rare occurrence in patients treated with venetoclax mono- or combination therapy, and clear protocols guiding TLS prophylaxis are lacking.
Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo   +3 more
doaj   +1 more source

DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu, Yuzhu Ma, Yueying Gao, Yao Chen, Xinyu Li, Yue Wu, Meiling Sun, Qizhao Li, Yanhong Zhao, Shuqian Xu, Shengjin Fan, Yongsheng Li, Huitao Fan   +12 more
wiley   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1‐Mutated Acute Myeloid Leukemia

Cancer Medicine
Background ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse‐risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria.
Yiming Cai, Jingwen Rui, Zhengwen Ding, Judan Xie, Zhou Jin, Jinyan Xiao, Yang Xu   +6 more
doaj   +1 more source

Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapies

HemaSphere, Volume 10, Issue 2, February 2026.
Abstract Prognosis in therapy‐related acute myeloid leukemia (T‐AML) remains poor, but understanding outcomes with venetoclax (VEN)‐based therapy is relevant. We retrospectively analyzed 317 adult patients with newly diagnosed T‐AML focusing on lower intensity therapy (LIT) VEN‐containing regimens.
Jayastu Senapati, Jennifer Croden, Guillermo Garcia‐Manero, Koichi Takahashi, Naval G. Daver, Tapan M. Kadia, Gautam Borthakur, Nicholas James Short, Elias Jabbour, Fadi Haddad, Jennifer Marvin‐Peek, Hussein A. Abbas, Prithviraj Bose, Guilin Tang, Sanam Loghavi, Elizabeth J. Shpall, Jeremy Ramdial, Uday R. Popat, Richard E. Champlin, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. Dinardo   +21 more
wiley   +1 more source

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress

Journal of Experimental & Clinical Cancer Research
Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy.
Jenna L. Carter, Yongwei Su, Eman T. Al-Antary, Jianlei Zhao, Xinan Qiao, Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Steven A. Buck, Maik Hüttemann, Joshua E. Allen, Varun V. Prabhu, Jay Yang, Jeffrey W. Taub, Yubin Ge   +17 more
doaj   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Low molecular weight compounds from mushrooms as potential Bcl-2 inhibitors: docking and virtual screening studies [PDF]

, 2016
Mestrado com dupla diplomação com o Institut Superieur de Biotechnologie de MonastirMushrooms have the ability to promote apoptosis in tumor cell lines, but the mechanism of action is not quite well understood. Inhibition of the interaction between Bcl-2
Khelifa, Sabrine
core  

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source